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1. SUMMARY 
The synthesis of eight Ru complexes with the general formula [RuI2(h6-arene)(PPyrR2)] (Pyr 
= 1-pyrenyl; arene = methyl benzoate or p-cymene), is described. These species were obtained 
from the parent dichlorocomplexes by treatment with an excess of sodium iodide in refluxing 




Ru1-Ru4 stands for p-cymene complexes while Ru1’-Ru4’ are methyl benzoate complexes. 
Their structures were confirmed by IR, multinuclear NMR (31P, 1H, 13C), MS, EA and in three 
cases by single crystal X-ray diffraction. The antitumoral activity of these iodinated ruthenium 
complexes was studied against several cell lines and the results are promising compared to the 
chlorocomplexes. 
The synthesis of five new (1-pyrenyl)phosphines is also described. These ligands were 
designed taking into account the relation between the antitumoral activity and the bulkiness of the 






These phosphines were prepared adapting literature methods and have been characterised 
















R1 = R2 = i-Pr; Ru1
R1 = R2 = Ph; Ru2
R1 = Me, R2 = Ph; Ru3
R1 = R2 = Me; Ru4
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2. RESUM 
En aquest projecte es descriu la síntesi de vuit complexos de ruteni amb fórmula general 
[RuI2(h6-arè)(PPyrR2)] (Pyr = 1-pirenil; arè = benzoat de metil o p-cimè). Aquests compostos es 
van obtenir a partir dels diclorocomplexos per tractament amb un excés de iodur de sodi en 




Ru1-Ru4 són els complexos amb p-cimè mentre Ru1’-Ru4’ els de benzoat de metil. 
Les estructures dels complexos s’han pogut confirmar mitjançant IR, RMN multinuclear (31P, 
1H, 13C), MS, EA i per difracció de raig X de monocristall per tres dels compostos. L’activitat 
antitumoral d’aquests complexos iodats s’ha estudiat en diferents línies cel·lulars i és 
prometedora comparat amb els complexos clorats. 
També es descriu la síntesi de cinc noves (1-pirenil)fosfines, les quals es van dissenyar per 
la relació estructura-activitat que presentaven els lligands en els complexos clorats anàlegs. Tots 





La preparació d’aquestes fosfines es va dur a terme adaptant altres síntesis ja conegudes en 

















R1 = R2 = i-Pr; Ru1
R1 = R2 = Ph; Ru2
R1 = Me, R2 = Ph; Ru3
R1 = R2 = Me; Ru4
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antitumorals, compostos organometàl·lics, química bioorganometàl·lica. 
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3. INTRODUCTION 
In developed countries cancer is the second cause of death only after cardiovascular 
diseases whereas it is the third cause in developing ones. What is even worse is that the number 
of cancer deaths is continuously increasing. For that reason, many chemotherapeutic drugs have 
been synthetised to improve the survival rate. Some of these drugs are based on organic 
scaffolds but another important group are metallodrugs based on transition metals.[1] 
In 1965 Rosenberg[2] discovered that cisplatin had inhibited cell division in bacteria. Soon after 
it was found that this compound also presented a potent antitumoral effect and in 1978 it was 
approved as a chemotherapeutic drug against testicular and ovarian cancers. Nowadays platinum 
complexes are widely considered an achievement in the field of cancer treatment by 




Scheme 1. The most used chemotherapeutic platinum drugs. 
Despite the success of cisplatin and derivatives, these compounds present severe side-
effects (nephrotoxicity, neurotoxicity and ototoxicity…) and frequently tumoral cells develop 
resistance. In order to improve the antitumoral activity and reduce the side-effects, many other 
coordination compounds have been tested.  
Among the variety of metals that have been explored, it was found the exchange reaction in 
ruthenium complexes (specially aquation, which is very important for cytoxicity) are similar than 
the platinum ones and for that reason ruthenium-based systems have been studied in depth.[3] 
Additionally these compounds have shown other promising features, such as reduced toxicity and 
increased selectivity towards cancer cells than platinum. These advantages are believed to be 
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Scheme 2. Publication date of the most studied ruthenium chemotherapeutic drugs. 
The two lead ruthenium complexes are NAMI-A and KP1019, which are about to become 
marketable drugs due to their high selectivity against tumors. Regardless their differences, both 
are Ru(III) compounds that are believed to become active by reduction to Ru(II) species in the 
reducing tumoral medium. 
For that reason Ru(II) compounds stabilised by a h6-coordinated arene ligand were directly 
used.[1b,3b,3c,4] The most important, which present clinical studies, are the RAPTA family.[5] These 
neutral type of complexes are saturated (18 e-) with an octahedral geometry, which present a 
ligand disposition and are typically known as ‘piano-stool’. This name stems from the arene being 
the seat and the two chlorides and the phosphine the legs of the stool. 
The Homogeneous Catalysis group at the University of Barcelona developed a large number 
of complexes with general formula [RuCl2(h6-arene)(PR3)] with PR3 being a P-stereogenic 
phosphine and have been used in asymmetric reduction of ketones.[6] Given the similarity of these 
complexes with the RAPTA family, many of them were tested as antitumoral agents in 
collaboration with the Bioinorganic Chemistry group.[6b] It was found that the complexes with 




















































Scheme 3. IC50 values (µM) against SW620 (human colon carcinoma) cell line. 
For that reason a second generation of achiral 1-pyrenylphosphines was prepared and 
coordinated to the ruthenium precursors. After the antitumoral activity studies, structure-activity 
relationships were discovered. Regarding the phosphine, the more hindered produce the lowest 
activity while the p-cymene compounds are less active than the methyl benzoate analogues as is 










Scheme 4. IC50 values of Ru complexes against the SW620 (human colon carcinoma) cell line. 
Therefore the most active complex was found to be Ru4Cl’ bearing the less hindered 
dimethylphosphine and methyl benzoate. As it can be seen this precursor presents very promising 
cytotoxicity in the low µM range. 
From the literature it was found that in some cases changing chloride by iodide in ruthenium 
complexes produce more cytotoxic systems.[8] Therefore it seemed logical to prepare a third 
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This Final Project describes the work carried out on these new ruthenium compounds for 
use in biological studies, and the design of new unhindered 1-pyrenylphosphine ligands. 
  




• Synthesis and characterization of [RuI2(h6-arene)(PPyrR2)], where arene is methyl 
benzoate or p-cymene and R is methyl, isopropyl or phenyl. 
•  Synthesis and characterization of new 1-pyrenylphosphines (L4 – L8) from the 
already known dichloro(1-pyrenyl)phosphine (L0). 
 








5. RESULTS AND DISCUSSION 
5.1. SYNTHESIS OF [RUI2(h6-ARENE)(PPYRR2)] 
The first experiment was started by mixing L2 and D1 in dichloromethane following the typical 




Scheme 5. Preparation of Ru2I by splitting of D1. 
 After the work-up the crude was analysed by 31P{H}, which showed a major peak at 23.4 ppm 
accompanied by another resonance at 18.1 ppm and many other small peaks due to the oxidation 
and hydrolysis of the phosphine. The recrystallisation of the crude gave a solid whose 31P{1H} 
NMR showed the two peaks in a 1:0.7 ratio. As it will be shown below, the peak at lower field 
corresponds to Ru2I, while the identity of the other compound remains a mystery. Since the 
desired product could not be obtained pure by this method an alternative one was envisaged.  
The second strategy was to exchange the Cl ligands of Ru1Cl’ by I. To this end, this complex 
was dissolved in dichloromethane and vigorously stirred with concentrated aqueous KI, forming 
a biphasic system.[9] The reaction was successful and after 72 h the pure desired product Ru1I’ 
was isolated in 49% yield. Unfortunately, when the same conditions were applied to Ru2Cl’ a 1:2 
ratio between Ru2Cl’ and Ru2I’ respectively was observed after a week. As the last attempt, the 
reaction mixture was heated for 16 h at 45 ºC, but the product ratio remained unchanged.  
Finally, the exchange reaction was performed in acetone at reflux, following the method of 
Hudson and Simpson.[10] The first complex attempted was Ru1Cl’, hence the complex and a 








P RuI I P
D1 L2 Ru2I
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several hours. Interestingly if extra pure acetone was used, the reaction was slower, therefore 
the presence of water probably speeds up the reaction. 
The reaction time needed to reach full conversion depended strongly on the complex (Table 
1).  








Ru4’ 264 (11 days) 
Table 1. Reaction times required to reach full conversion. 
From the table it can be concluded the bulkiness of the phosphine and the electronic nature 
of the h6 coordinated arene ring affects the exchange rate. 
Fortunately the reactions could be easily monitored by 31P NMR spectroscopy, for example 
Figure 1 shows the evolution of the exchange reaction for Ru4Cl’. 
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Figure 1. 31P NMR monitoring of the exchange reaction from Ru4Cl’ (+9.6 ppm) to Ru4I’ (–5.2 ppm). 
Bottom to top: 1, 2, 3, 7 and 11 days. 
For an 18-electron octahedral complex a dissociative mechanism for ligand exchange 
reactions can be envisaged. In this kind of mechanisms the rate-limiting step is the departure of 
a ligand, consequently, the bulkier the ancillary ligand, the faster the exchange. This fits with the 
fact that the exchange in complexes Ru4 and Ru4’, bearing dimethyl phosphine (the less 
hindered ligand) needs a longer reaction time. The crowding, however, is not the only important 
factor, the electronic nature of the arene also affects the rate. It can be expected that electron-
richer arenes should make the Ru-arene bond stronger which, in turn, should make the Ru-Cl 
bond weaker, increasing the reaction rate. This is in accordance with the observation that the p-
cymene complexes react faster. 
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The complexes were obtained after an extractive work-up and recrystallisation as brown dusty 
solids in yields between 37 and 75 %. Those complexes requiring longer reaction time had the lowest 
yields.  
This type of complexes have been fully characterised by the usual techniques. Mass 
Spectrometry (MS) displayed the same characteristic m/z peak corresponding to [M – I]+ analogously 
to the chlorocomplexes described in the literature.[6e] As expected the IR of Ru1I’-Ru4I’ showed a 
strong band around 1730 cm–1 due to C=O stretching of the carboxylate. 
31P NMR spectroscopy showed a single resonance for all complexes shifted to higher fields from 
the parent chlorocomplexes (Table 2). 
 
Complexes Cl2 I2 Dd 
Ru1 +36.3 +31.3 -5 
Ru1’ +38.9 +34.5 -4.4 
Ru2 +32.1 +23.4 -8.7 
Ru2’ +32.1 +22.4 -9.7 
Ru3 +17.2 +10.3 -6.9 
Ru3’ +16.7 +9.7 -7.0 
Ru4 +7.7 -5.8 
-
13.5 
Ru4’ +9.6 -5.2 
-
14.8 
Table 2. 31P chemical shifts of ruthenium complexes. 
Owing to the lower electronegativity of iodine compared to chlorine, the P atoms in 
iodocomplexes appear more shielded. 
In 1H NMR spectra there are 3 regions of chemical shifts: the highest shift which is part of aromatic 
zone (9.5 – 7.5 ppm), followed by the coordinated arene (5.5 – 4.0 ppm) and finally there is the 
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 Figure 2. 1H NMR spectrum of complex Ru4I. 
Only one of the phosphines (L3) is chiral, so it is expected for Ru3I and Ru3I’ to have all the 
protons non-equivalent. The reason is that these complexes do not have any symmetry element. 
This is indeed the case and hence four and five resonances can be observed in the arene 
coordinated region for Ru3I and Ru3I’ respectively. 
On the other hand, the phosphines of the rest complexes are achiral, so the 1H NMR spectra 
some of the protons should be equivalent. This supposition is correct except interestingly in the 
case of complexes Ru1, in which all the protons are non-equivalent, like Ru3. This may be due 
to the bulkiness of L1, which could slow down the rotation of the arene.  
Similar trends could be observed in 13C NMR spectra, which could be assigned thanks to 
bidimentional 1H – 13C HSQC experiments.  
Single crystals, suitable for X-ray crystallography, could be obtained for complexes Ru2I’, 
Ru3I and Ru4I by diffusion of hexane into dichloromethane solutions of the complexes. The 
diffraction experiments were performed in the Advanced Light Source synchrotron facility of the 
Berkeley University. The representation of their molecular structures is given in Figure 3 and 
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Figure 3. From left to right: ORTEP representations of Ru2I’, Ru3I and Ru4I with the thermal ellipsoids 
drawn at the 50% probability level and H atoms omitted for clarity. 
As expected the complexes adopt the typical three-legged piano stool geometry. The 1-
pyrenyl group of the phosphine point outwards the ruthenium center, probably due to steric 
reasons. In complex Ru3I the phosphine would have S absolute configuration as a free ligand, 
as expected.[11] 








Ru–P 2.3814(7) 2.3470(14) 2.346(2) 
P–CPyr 1.836(3) 1.839(6) 1.837(12) 
P–CPh 
1.837(3) 
1.830(3) 1.842(6) – 










I–Ru–I 86.482(10) 88.063(16) 86.44(3) 
Table 3. Selected distances (Å) and angles (º) for complexes Ru2I’, Ru3I and Ru4I. 
Distances and angles are in the normal range for this type of complexes. It is observed that 
the bulkier the phosphine, the longer the Ru–P distance. Interestingly the Ru–I distances are 
considerably larger than Ru–Cl of related complexes.[6a,6c,6e] 
Preliminary studies were carried out on the cytotoxicity of iodinated ruthenium compounds to 
compare with the parent chlorocomplexes. Table 4 gives the IC50 values of Ru1I and Ru1Cl 
against SW620 (human colon carcinoma), A375 (human melanoma) and MCF7 (breast 
carcinoma). 





Table 4. IC50 values of Ru1I and Ru1Cl. 
Encouragingly, the table shows that Ru1I is approximately twice as active compare to Ru1Cl. 
Taking into account that Ru1 is the less active, much better results can be expected for the rest of 
the iodocomplexes. These studies are currently underway. 
 
5.2. SYNTHESIS OF NEW 1-PYRENYLPHOSPHINES 
After the successful synthesis of the ruthenium compounds, the synthesis of new phosphines 
was undertaken following literature methods for similar ligands. The 1-pyrenylphosphines 
prepared are shown in Scheme 6.  
Scheme 6. Preparation of 1-pyrenylphosphines with their chemical shift. 
Complexes SW620 A375 MCF7 
Ru1Cl 13.41 16.58 22.96 
Ru1I 6.44 9.18 10.56 

























+159.7 ppm +100.9 ppm
-59.7 ppm
-129.7 ppm
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The synthesis of L0 was adapted from the method described by Baumgartner and 
coworkers.[12] L0 is a versatile synthon owing to the reactivity of the P-Cl bond with nucleophilic 
species. Our aim, as discussed in the Introduction, was to obtain new PPyrR2 where R is an 
unhindered group. 
To obtain L0, 1-bromopyrene was lithiated at low temperature and the formed 1-pyrenyllithium 
was reacted with bis(diethylamino)chlorophosphine, producing bis(diethylamino)(1-
pyrenyl)phosphine, which was detected as a singlet at +100 ppm in 31P NMR. This compound 
was hydrolysed with dry hydrogen chloride in diethyl ether, which yielded the desired product as 
a yellow solid.[12] 
Reacting L0 with dimethylamine or methanol in the presence of NEt3, L7 and L8 were 
obtained respectively, after the filtration of the ammonium salts.[13] These products were isolated 
and characterised and their 31P chemical shifts were in the similar range of other related 
compounds[13]. In 1H NMR is observed that the methyl groups are equivalent and appear as 
doublets due to the coupling with the phosphorus. 
The reaction of L0 with MeMgCl cleanly afforded the known ligand L4,[7] which was detected 
as a singlet at –60 ppm in 31P NMR and was directly used for the synthesis of Ru4. Interestingly, 
using MeMgCl instead of the pyrophoric chlorodimethylphosphine makes easier the synthesis of 
these complexes.  
If L0 is reacted with lithium aluminium hydride, the primary phosphine (L5) is obtained and 
appears at –129.7 ppm in 31P NMR spectrum (Figure 4).[14] 
  











Figure 4. Comparison of 31P (top) and 31P{1H} (bottom) of L5. 
In this case the 1H-coupled 31P NMR was also recorded. As expected a triplet with a 1JPH of 
204 Hz was found, but it had a fine structure of doublet of triplets, due to the coupling with the 
pyrenyl protons.  
To obtain the phosphirane (L6), L5 was deprotonated with methyllithium and the dianion was 
treated with 1,2-dichloroethane.[13,14c] The compound L6 was isolated and characterised and in 
the 31P NMR appears as a singlet at –236 ppm, a chemical shift typical for this kind of 
phosphines.[13,14c] Two multiplets of two protons are observed in 1H NMR. 
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6. EXPERIMENTAL SECTION 
6.1. MATERIALS AND METHODS 
All compounds were prepared under a purified nitrogen atmosphere by standard Schlenk and 
vacuum-line techniques. The solvents were obtained from solvent-purification system or purified 
by standard procedures and kept under nitrogen. 1H, 13C{1H}, 31P{1H} and HSQC 1H-13C NMR 
spectra were recorded with 400 MHz spectrometers with CDCl3 as solvent unless otherwise 
specified. The IR spectra were recorded in KBr, and the main absorption bands are expressed in 
cm–1. High-resolution mass spectrometry analyses were performed with electrospray ionisation. 
Elemental C, H analyses were performed at the Centres Científics i Tecnològics (CCiT) of the 
Universitat de Barcelona.  
6.2. PREPARATION OF RUTHENIUM COMPLEXES 
6.2.1. Ru1I 
A suspension of Ru1Cl (423 mg, 0.68 mmol) and NaI (1.5 g, 10 mmol) in technical grade 
acetone (40 mL) was heated under reflux for 4 h protected from light. The solvent was removed 
under reduced pressure and the crude was extracted with dichloromethane/water. The combined 
organic phase was dried with anhydrous Na2SO4 and filtered. After elimination of the solvent, the 
crude was crystallised from dichloromethane and hexane and finally washed with pentane. Yield 
410 mg (75%). 
 Brown solid. IR: 2952, 2926, 2870, 1448, 1200, 1026, 848, 609, 509. 
31P{1H} NMR: δ +31.3 (s). 1H NMR: δ 8.96 (d, J = 9.6, 1H), 8.51 (t, J = 8.4, 
1H), 8.32-8.23 (m, 4H), 8.20 (d, J = 8.8, 1H), 8.13 (d, J = 10.0, 1H), 8.09 (d, 
J = 7.6, 1H), 5.50 (s, br, 1H), 4.86 (s, br, 1H), 4.70 (s, br, 1H), 4.40 (s, br, 
1H), 4.27 (s, br, 1H), 3.54 (s, br, 1H), 3.34 (sept, J = 6.8, 1H), 1.85 (s, br, 
3H), 1.69 (s, 3H), 1.67 (s, br, 3H), 1.43 (s, br, 3H), 1.26 (s, br, 3H), 0.96 (s, 
br, 3H), 0.63 (s, br, 3H). 13C{1H} NMR: δ 133.2-123.1 (C, CH, Ar), 87.8-86.5 
(4CH), 31.2 (CH), 23.7 (br, 2CH3), 21.8 (br, CH3), 20.2 (br, CH3), 19.6 (br, 
CH3), 18.9 (CH3), 18.7 (br, CH3), HRMS (ESI): m/z calc. for C32H37IPRu [M 
– I]+ 681.0715; found 681.0720. EA: calc. for C32H37I2PRu C (47.60%), H 
(4.62%); found C (45.71%), H (4.74%). 
Ru
I I P
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6.2.2 Ru1I’ 
The procedure was the same used to obtain Ru1I but starting from Ru1Cl’ (470 mg, 0.75 
mmol) and keeping the reaction 16 h at reflux. Yield: 435 mg (72%).  
 
 Brown solid. IR: 3052, 2961, 2926, 2865, 1735, 1430, 1296, 1265, 
1104, 848, 761, 604. 31P{1H} NMR: δ +34.5 (s). 1H NMR: δ 9.03 (d, J = 9.2, 
1H), 8.52 (t, J = 8.4, 1H), 8.34-8.20 (m, 5H), 8.15-8.10 (m, 2H), 6.49 (t, J = 
5.6, 1H), 6.37 (d, J = 5.6, 1H), 5.24 (t, J = 5.6, 1H), 4.55 (dd, J = 9.6, J = 
5.2, 1H), 4.39 (t, J = 5.2, 1H), 4.26 (dd, J = 14.0, J = 6.8, 1H), 3.98 (s, 3H) 
, 3.57 (dd, J = 14.8, J = 7.6, 1H), 1.85 (dd, J = 16.4, J = 7.6, 3H), 1.71 (dd, 
J = 11.2, J = 7.2, 3H), 1.46 (dd, J = 16.0, J = 7.2, 3H), 0.66 (dd, J = 13.2, J 
= 7.2, 3H). 13C{1H} NMR: δ 164.4 (CO), 133.4-123.7 (C, CH, Ar), 93.6 (CH), 
93.2 (CH), 90.3 (CH), 89.0 (d, J = 9.4, C), 86.9 (CH), 83.6 (CH), 53.7 (CH3), 
30.3 (d, J = 25.7, CH), 29.4 (d, J = 25.3, CH), 23.2 (CH3), 20.1 (d, J = 7.0, 
CH3), 19.8 (d, J = 7.2, CH3), 18.3 (CH3). HRMS (ESI): m/z calc. for 
C30H31O2IPRu [M – I]+ 683.0144; found 683.0142.  
6.2.3 Ru2I 
The procedure was the same used to obtain Ru1I but starting from Ru2Cl (450 mg, 0.68 
mmol) and keeping the reaction 4 h at reflux. Yield: 369 mg (62%).  
 
 Brown solid. IR: 3048, 2957, 2917, 2861, 1470, 1430, 1374, 1087, 852, 
687, 635, 539, 513, 461. 31P{1H} NMR: δ +23.4 (s). 1H NMR: δ 8.62 (d, br 
1H), 8.28 (d, J = 7.2, 1H), 8.23-8.05 (m, 6H), 7.96 (d, J = 9.2, 1H), 7.73 (s, 
br, 4H), 7.35 (s, br, 6H), 5.43 (s, br, 2H), 4.67 (s, br, 2H), 3.53 (sept, J = 
6.8, 1H),1.79 (s, 3H), 1.23 (s, br, 6H). 13C{1H} NMR: δ 135.2-123.5 (C, CH, 
Ar), 112,6 (d, J = 5.9, C), 100.7 (C), 88.5 (d, J = 3.8, 2CH), 88.0 (2CH), 31.9 
(CH), 22.7 (br, 2CH3), 19.0 (CH3). HRMS (ESI): m/z calc. for C38H33IPRu 
[M – I]+ 749.0402; found 749.0413. EA: calc. for C38H33I2PRu C (52.13%), 
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6.2.4 Ru2I’ 
The procedure was the same used to obtain Ru1I but starting from Ru2Cl’ (493 mg, 0.71 
mmol) and keeping the reaction 16 h at reflux. Yield: 373 mg (60%). 
 
 Brown solid. IR: 3065, 2917, 1726, 1435, 1287, 1109, 857, 709, 517. 
31P{1H} NMR: δ +22.4 (s). 1H NMR: δ 8.74 (d, J = 9.2, 1H), 8.31-8.03 (m, 
7H), 7.81-7.10 (m, 11H), 6.50 (s, br, 2H), 5.04 (s, br, 2H), 4.94 (m, 1H), 3.99 
(s, 3H). 13C{1H} NMR: δ 164.2 (CO), 135.5-123.9 (C, CH, Ar), 90.9 (3CH), 
88.3 (2CH), 53.3 (CH3). HRMS (ESI): m/z calc. for C36H27IO2PRu [M – I]+ 
750.9831; found 750.9862. EA: calc. for C36H27I2O2PRu C (49.28%), H 
(3.10%); found C (48.98%), H (3.31%). 
6.2.5 Ru3I 
The procedure was the same used to obtain Ru1I but starting from Ru3Cl (150 mg, 0.24 
mmol) and keeping the reaction 8 h at reflux. Yield: 93 mg (48%). 
 
 Brown solid. IR: 2952, 2917, 1638, 1618, 1439, 1384, 1026, 895, 849, 
718, 629. 31P{1H} NMR: δ +10.3 (s). 1H NMR: δ 8.80 (d, J = 12.8, J = 8.0, 
1H), 8.30-7.75 (m, 10H), 7.43-7.33 (m, 3H), 5.50 (d, J = 6.0, 1H), 5.35 (d, J 
= 4.4, 1H), 5.17 (d, J = 6.8, 1H), 5.12 (d, J = 6.0, 1H), 3.04 (m, 1H), 2.81 (d, 
J = 9.6, 3H), 2.32 (s, 3H), 0.74 (d, J = 7.2, 3H), 0.42 (d, J = 6.8, 3H). 13C{1H} 
NMR: δ 133.4-123.8 (C, CH, Ar), 110,6 (C), 96.8 (C), 91.4 (CH), 89.2 (CH), 
88.4 (CH), 83.9 (CH), 31.6 (CH), 23.22 (d, J = 38.9, CH3), 22.7 (CH3), 20.4 
(CH3), 19.4 (CH3). HRMS (ESI): m/z calc. for C33H31I2PRu [M – I]+ 687.0246; 
found 687.0248. EA: calc. for C33H31I2PRu C (48.73%), H (3.84%); found C 
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6.2.6 Ru3I’ 
The procedure was the same used to obtain Ru1I but starting from Ru3Cl’ (301 mg, 0.48 
mmol) and keeping the reaction 4 h at reflux. Yield: 210 mg (54%). 
 
 
Brown solid. IR: 2904, 2848, 1731, 1638, 1618, 1434, 1384, 
1275, 1114, 616. 31P{1H} NMR: δ +9.7 (s, br). 1H NMR: δ 8.74 
(dd, J = 12.8, J = 8.0 1H), 8.34-7.95 (m, 8H), 7.79-7.74 (m, 2H), 
7.41-7.31 (m, 3H), 6.51 (d, J = 6.4, 1H), 6.30 (s, br, 1H), 5.60 (t, J 
= 4.0, 1H), 5.33 (t, J = 6.0, 1H), ), 5.06 (s, br, 1H), 3.85 (s, 3H), 
2.90 (d, J = 10.4, 3H. 13C{1H} NMR: δ 164.5 (CO), 133.6-124.0 
(C, CH, Ar), 93.1 (CH), 93.1 (CH), 90.2 (CH), 87.4 (CH), 87.2 (CH) 
86.3 (CH), 53.1 (CH3), 23.7 (d, J =35.2, CH3). HRMS (ESI): m/z 
calc. for C31H25O2IPRu [M – I]+ 688.9674; found 688.9682. 
 
6.2.7 Ru4I 
The procedure was the same used to obtain Ru1I but starting from Ru5Cl (230 mg, 0.40 
mmol) and keeping the reaction 24 h at reflux. Yield: 206 mg (68%). 
 
 
Brown solid. IR: 2957, 2917, 1624, 1430, 1383, 913, 845, 719, 
698, 600, 532. 31P{1H} NMR: δ –5.8 (s). 1H NMR: δ 9.32 (d, J = 9.6, 
1H), 8.40-8.09 (m, 8H), 5.06 (d, J = 6.0, 2H), 4.78 (s, br, 2H), 3.14 
(sept, J = 6.8, 1H), 2.46 (d, J = 9.2, 6H), 1.98 (s, 3H), 1.06 (d, J = 7.2, 
6H). 13C{1H} NMR: δ 133.2-123.8 (C, CH, Ar), 110,6 (C) 97.3 (C), 90.1 
(d, J = 15.6, 2CH), 85.2 (br, 2CH), 31.7 (CH), 22.4 (br, 4CH3), 19.9 
(CH3). HRMS (ESI): m/z calc. for C28H29IPRu [M – I]+ 625.0089; found 
625.0090. EA: calc. for C28H29I2PRu C (44.76%), H (3.89%); found C 














The procedure was the same used to obtain Ru1I but starting from Ru5Cl’ (240 mg, 0.42 
mmol) and keeping the reaction 11 days at reflux. Yield: 116 mg (37%). 
 
 Brown solid. IR: 3065, 3035, 1935, 1733, 1288, 1270, 913, 849. 
31P{1H} NMR: δ –5.2 (s). 1H NMR: δ 9.31 (d, J = 9.6, 1H), 8.51-8.10 
(m, 8H), 6.25 (s, br, 2H), 5.70 (t, J = 5.6, 1H), 4.91 (s, br, 2H), 3.90 (s, 
3H), 2.49 (d, J = 9.6, 6H). 13C{1H} NMR: δ 165.2 (CO), 130.5-123.9 (C, 
CH, Ar), 93.0 (CH), 53.0 (CH3), 20.4 (CH3). HRMS (ESI): m/z calc. for 
C26H23IO2PRu [M – I]+ 626.9518; found 626.9518. EA: calc. for 
C26H23I2O2PRu C (41.45%), H (3.08%); found C (41.25%), H (3.32%). 
 
6.3. PREPARATION OF PHOSPHINES 
6.3.1. L4 
MeMgCl (3.3 mL, 3 M in THF, 10 mmol) was added to a solution of L0 (1.5 g, 5 mmol) in THF 
(50 mL) previously cooled to –78 ºC, stirred for 3 h and the mixture was allowed to warm up to 
room temperature. At this point, the reaction was quenched with MeOH (1 mL) and the solution 
of the phosphine was ready to be used. 
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6.3.2. L5 
To a suspension of LiAlH4 (382 mg, 10.1 mmol) in THF (40 mL) cooled at –78 ºC, L0 (1.5 g, 
5 mmol) dissolved in THF (30 mL) was added dropwise during 2 h and the mixture was allowed 
to reach room temperature overnight. To the brown suspension a thoroughly degassed aqueous 
solution of NH4Cl was carefully added and the THF was eliminated under vacuum. Always under 
N2, the mixture was extracted with dichloromethane, the organic phase dried with Na2SO4, 




Yellow solid. 31P{1H} NMR: δ –129.7 (s). 31P NMR: δ –129.7 (tdt, 
J = 204.3, J = 7.3, J = 1.1). 1H NMR: δ 8.41 (dd, J = 9.2, J = 2.0, 1H), 
8.23-7.99 (m, 8H), 4.45 (d, J = 204, 2H). 13C{1H} NMR: δ 133.7-122.6 
(C, CH, Ar).  
6.3.3. L6 
MeLi (2.6 mL, 1.6 M in diethyl ether, 4.18 mmol) was added to a suspension of L5 (445 mg, 
1.9 mmol) in THF (10 mL) precooled at –78 ºC and the purple solution was stirred for 30 min. 
1,2-Dichloroethane (0.18 mL, 2.28 mmol) was added and the mixture was allowed to reach room 
temperature overnight. The reaction was quenched with MeOH (1 mL) and the THF was 
eliminated under vacuum. Always under N2, the mixture was extracted with dichloromethane, the 
organic phase dried with Na2SO4, decanted and the solvent removed under reduced pressure to 
give a yellow product. Yield 452 mg (91%). 
 
 
Yellow solid. 31P{1H} NMR (C6D6): δ –235.8 (s). 1H NMR (C6D6): δ 
9.00 (dd, J = 9.2, J = 2.8 1H), 7.91-7.68 (m, 8H), 1.29-1.25 (m, 2H), 
1.16-1.08 (m, 2H). 13C{1H} NMR (C6D6): δ 136.8-124.7 (C, CH, Ar), 
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6.3.4. L7 
NEt3 (2.0 mL, 14 mmol) and HNMe2 (2.6 mL, 5.2 mmol) were subsequently added to a 
suspension of L0 (758 mg, 2.5 mmol) in THF (30 mL) and the solution was stirred overnight. The 
crude product was filtered and the solvent removed under reduced pressure to give a yellow 
product. Yield 755 mg (94%). 
 
 
Yellow solid. 31P{1H} NMR: δ +100.9 (s). 1H NMR: δ 8.57 (d, J 
= 9.2, 1H), 8.21-7.98 (m, 8H), 2.86 (d, J = 8.8, 12H). 13C{1H} NMR: 
δ 134.8-124.3 (C, CH, Ar), 41.6 (d, J = 16.3, 4CH3).  
6.3.5. L8 
NEt3 (2.0 mL, 14 mmol) and MeOH (0.25 mL, 5.5 mmol) were subsequently added to a solution 
of L0 (758 mg, 2.5 mmol) in dichloromethane (20 mL) and the solution was stirred for 2 h. The 
suspension was filtered and the filtrate was concentrated to dryness under reduced pressure to 
give a yellow product. Yield 582 mg (79%). 
 
 
Yellow solid. 31P{1H} NMR: δ +159.7 (s). 1H NMR: δ 8.68 (dd, J = 
9.2, J = 3.6, 1H), 8.29 (dd, J = 7.6, J = 3.2, 1H), 8.07-7.84 (m, 7H), 3.52 
(d, J = 10.8, 6H). 13C{1H} NMR: δ 133.0-123.7 (C, CH, Ar), 53.5 (d, J = 
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7. CONCLUSIONS 
• The iodinated ruthenium complexes (Ru1-Ru4) were successfully obtained from 
the analogous chloro complexes by substitution with sodium iodide. 
• The reaction rate strongly depends on the starting complex structure. Those 
containing the p-cymene group react faster than those with the methyl benzoate. 
Regarding the phosphine, unhindered ancillary ligands give slower reactions. 
Unfortunately, long reaction times produce low yields due to the decomposition of 
the complexes. 
• In 1H NMR of some complexes, extra peaks were observed, which may belong to 
the presence of different rotamers. 
• The preliminary cytotoxicity studies of Ru1I against several cell lines show that this 
complex is more active than Ru1Cl. 
• From the described precursor L0, new 1-pyrenylphospine ligands (L4-L8) were 
obtained following literature methods for similar substrates. 
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9. ACRONYMS 
EA: Elemental Analysis 
HRMS: High Resolution Mass Spectroscopy 
HSQC: Heteronuclear Single Quantum Coherence spectroscopy 
IC50: Half Maximal Inhibitory Concentration 
IR: Infrared spectroscopy 
NMR: Nuclear Magnetic Resonance 
THF: Tetrahydrofuran 
XRD: X-Ray Diffraction 
 

 
 
